This is an investigational study. Gemcitabine is FDA approved for the treatment of breast cancer when given in combination with paclitaxel. Gemcitabine will not be provided free of charge. CT-2103 is not yet FDA approved and will be provided free of charge during the study. Any laboratory testing that is not standard of care will be paid for by the supporting company. About 18 women will take part in this study. All will be enrolled at M. D. Anderson.